Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 5,020.00
-60.00 (-1.18%)
At close: Jan 13, 2026
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
93.08M JPY
Profits / Employee
696.98K JPY
Market Cap
7.93T
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HOYA Corporation | 37,909 |
| Otsuka Holdings | 35,338 |
| Olympus | 29,297 |
| Daiichi Sankyo Company | 19,765 |
| M3, Inc. | 15,360 |
| Astellas Pharma | 13,643 |
| Eisai | 10,917 |
| Kyowa Kirin | 5,669 |
Takeda Pharmaceutical Company News
- 13 hours ago - Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 hours ago - Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 8 days ago - Takeda Pharmaceutical, Protagonist Therapeutics Announces Submission Of NDA For Rusfertide - Nasdaq
- 8 days ago - Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) - Business Wire
- 26 days ago - Takeda's Once-Daily Psoriasis Pill Hits Phase 3 Goals, Beats Amgen's Drug - Benzinga
- 26 days ago - Takeda's AI-crafted psoriasis pill succeeds in late-stage studies - Reuters
- 26 days ago - Takeda's Phase 3 Study Of Oral Zasocitinib In Plaque Psoriasis Achieves Primary Endpoints - Nasdaq
- 26 days ago - Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment - Business Wire